Overview
- 2 public-safe observations are available for this inspection.
- 1 structured CFR citation is represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
24 Sep 2019
21 CFR 106.55(c)
Production aggregate sample - final stage, distribution
Cited by Dariusz Galezowski, Daniel B Arrecis
24 Sep 2019
21 CFR 106.55(c)
Production aggregate sample - final stage, distribution
Cited by Dariusz Galezowski, Daniel B Arrecis
Inspected site
ALAbbott LaboratoriesSturgis, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 106.55(c) | Cited across public-safe Form 483 observations | 2x |
Source document
PDF
PDF available
Form 483 source document
The source document is available to authorized Atlas users.
Full 483 report
Get the verbatim text of all 2 observations
The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere